Triasima Portfolio Management’s Abbott ABT Stock Holding History

Triasima Portfolio Management’s Portfolio ABT Stock Details ABT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-26,875	Closed	-$3.6M	–	144
2025 Q3	$3.6M	Buy	26,875 +10,590	+65%	+$1.39M	0.54%	62
2025 Q2	$2.21M	Buy	+16,285	New	+$2.15M	0.4%	84

Other funds holding ABT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Triasima Portfolio Management's ABT Position: Q4 2025 in Review

Triasima Portfolio Management sold out of Abbott (ABT) in Q4 2025, closing a stake of 26,875 shares — an estimated $3.6M sold.

Triasima Portfolio Management first reported a position in ABT in Q2 2025 and held it in 2 quarters. The position peaked at $3.6M in Q3 2025. 3,284 funds tracked by Wall St. Rank hold ABT as of Q4 2025.

Triasima Portfolio Management reported no remaining Abbott position as of Q4 2025 after selling out during the quarter.
Triasima Portfolio Management sold 26,875 Abbott shares in Q4 2025, an estimated $3.6M.
Triasima Portfolio Management first reported a position in Abbott in Q2 2025 and held it in 2 quarters.
Triasima Portfolio Management's Abbott position peaked at $3.6M in Q3 2025.
3,284 funds tracked by Wall St. Rank held Abbott as of Q4 2025.

Based on Triasima Portfolio Management's 13F filing for Q4 2025, filed 2 Feb 2026.